Nektar Therapeutics
NKTRAlgoritmens signaler
- ›Starkt 3m-momentum (+120.4%)
- ›Starkt 6m-momentum (+39.5%)
- ›Starkt 12m-momentum (+654.3%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (111% årlig)
- ›+949% från 52v-botten
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsNektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets
14 h sedanNektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO, April 28, 2026 SAN FRANCISCO , April 28,
Nektar TherapeuticsPR NewswireNektar sets May 7 earnings release, webcast starts 5 p.m. ET - Stock Titan
14 h sedanNektar sets May 7 earnings release, webcast starts 5 p.m. ET Stock Titan
Stock TitanThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR
23 h sedanThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2026 in Nektar Therapeutics Lawsuit - NKTR PR Newswire NEW YORK, April 28, 2026 NEW YORK , April 28, 2026 /PRNewswire/
Nektar TherapeuticsPR NewswireSHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
1 d sedanSHAREHOLDER ALERT Bernstein Liebhard LLP Announces A GlobeNewswire
GlobeNewswireWhy Nektar Therapeutics (NKTR) Is Down 8.6% After Raising Capital And Reporting New Alopecia Data - simplywall.st
2 d sedanWhy Nektar Therapeutics (NKTR) Is Down 8.6% After Raising Capital And Reporting New Alopecia Data simplywall.st
simplywall.stNKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
2 d sedanNKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit PR Newswire NEW YORK, April 27, 2026 NEW YORK , April 27, 2026 /PRNewswire/ -- Why: Rosen
Nektar TherapeuticsPR NewswireNKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill
2 d sedanNKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) ChartMill
ChartMillNektar Therapeutics prices $400M stock offering - MSN
2 d sedanNektar Therapeutics prices $400M stock offering MSN
MSNA Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Swings And REZPEG Progress - Sahm
5 d sedanA Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Swings And REZPEG Progress Sahm
SahmNektar Therapeutics closes $373.8M stock offering - Investing.com
5 d sedanNektar Therapeutics closes $373.8M stock offering Investing.com
Investing.comNektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
5 d sedanNektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SAN FRANCISCO, April 23, 2026 SAN F
Nektar TherapeuticsPR NewswireNektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
5 d sedanNektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire LOS ANGELES, April 23, 2026 LOS ANGELES , April 23, 2026 /PRNewswire/ -- The Law
Nektar TherapeuticsPR NewswireNKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Known Trial Defects: SueWallSt
5 d sedanNKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Known Trial Defects: SueWallSt PR Newswire NEW YO
Nektar TherapeuticsPR NewswireNKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
2026-04-22NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit PR Newswire NEW YORK, April 22, 2026 NEW YORK , April 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a gl
Nektar TherapeuticsPR NewswireNektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
2026-04-22Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering PR Newswire SAN FRANCISCO, April 21, 2026 SAN FRANCISCO , April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: N
Nektar TherapeuticsPR NewswireNKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
2026-04-21NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 PR Newswire NEW YORK, April 21, 2026 Faruqi & Faruqi, LLP
Nektar TherapeuticsPR Newswire